Recognition of non-operating expenses and extraordinary gains
Kidswell Bio Corporation (filing company)
Bank borrowings and part of the investment securities held by the company
Interest expense consisted of costs associated with bank borrowings and related items. Gains on the sale of investment securities were intended to strengthen the financial position and improve asset efficiency.
Interest expense: ¥45.414 million (non-operating expense); gains on sale of investment securities: ¥221.717 million (extraordinary gain)
Six-month cumulative interim consolidated period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026)
For the impact on business performance, refer to the "Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)," published today. No information was provided on whether the forecast was revised or on the revised figures.
For the impact on business performance, refer to the financial results summary published today. Other future actions and timing are Not disclosed.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating expenses and extraordinary gains |
| Date of occurrence | 1 April 2026 to 30 September 2026 (six-month cumulative interim consolidated period of the fiscal year ending March 2027) |
| Subject Entity | Kidswell Bio Corporation (filing company) |
| Target Locations / Products | Bank borrowings and part of the investment securities held by the company |
| Cause | Interest expense consisted of costs associated with bank borrowings and related items. Gains on the sale of investment securities were intended to strengthen the financial position and improve asset efficiency. |
| Amount of Impact on Business Performance | Interest expense: ¥45.414 million (non-operating expense); gains on sale of investment securities: ¥221.717 million (extraordinary gain) |
| Accounting period in which recognized | Six-month cumulative interim consolidated period of the fiscal year ending March 2027 (1 April 2026 to 30 September 2026) |
| Impact on Earnings Forecast | For the impact on business performance, refer to the "Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)," published today. No information was provided on whether the forecast was revised or on the revised figures. |
| Outlook | For the impact on business performance, refer to the financial results summary published today. Other future actions and timing are Not disclosed. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Interest expense arose as a cost associated with borrowings from banks and related items. The sale of investment securities was intended to strengthen the financial position and improve asset efficiency.